Prevalence,clinical features and treatment of depression in Parkinson’s disease:An update

• 作者: Omar ME Abdel-Salam
• 来源期刊: 世界神经病学杂志
• 学科: 医学
• 关键词: ANTIDEPRESSANT drugs DEPRESSION SEROTONIN REUPTAKE inhibitors Parkinson’s disease TRICYCLIC antidepressants
• 年，卷（期）: sjsjbxzz_2015,（1）
• 页码范围: 17-38
• 页数: 22页
• 分类号: R743.3

摘要

Parkinson’s disease(PD)is one of the most prevalent neurodegenerative diseases which typically affects individuals over 65 years.Although the symptomatology is predominantly motor,neuropsychiatric manifestations,e.g.,depression,apathy,anxiety,and cognitive impairment occur in the course of the illness and can have a great impact on the quality of life in these patients.Parkinson’s disease is commonly comorbid with depression with prevalence rates of depression,generally higher than those reported in general population.Depression in PD is frequently underestimated and consequently undertreated,which have significant effects on the quality of life in these patients.The neurobiology of depression in PD is complex and involves alterations in dopaminergic,serotonergic,noradrenergic and possibly other neurotransmitter systems which are affected in the course of the disease.The tricyclic antidepressants and the selective serotonin reuptake inhibitors are the two classes of antidepressant drugs used for depressive symptoms in PD.Several published studies suggested that both classes are of comparable efficacy.Other serotonergic antidepressants,e.g.,nefazodone and trazodone have also been of benefit.Meanwhile,there are limited data available on other drugs but these suggest a benefit from the serotonin and noradrenaline reuptake inhibitors such as mirtazapine,venlafaxine,atomoxetine and duloxetine.Some of the drugs used in symptomatic treatment of PD,e.g.,the irreversible selective inhibitors of the enzyme monoamine oxidase-B,rasagiline and selegiline as well as the dopamine receptor agonist pramipexole are likely to have direct antidepressant activity independent of their motor improving action.This would make these drugs an attractive option in depressed subjects with PD.The aim of this review is to provide an updated data on the prevalence,clinical features of depression in subjects with PD.The effects of antiparkinsonian and antidepressant drugs on depressive symptoms in these patients are also discussed.